A special enzyme injection given three times over six weeks can noticeably smooth out deep dimples on the buttocks in women with severe cellulite, and it works much better than a fake shot.
Scientific Claim
Subcutaneous injection of collagenase clostridium histolyticum-aaes (CCH-aaes) at 0.84 mg per treatment area, administered in three sessions over 43 days, causes a clinically significant improvement in the appearance of moderate-to-severe buttock cellulite in adult women, with 5.9 times greater odds of achieving a two-level improvement on both clinician- and patient-reported severity scales compared to placebo.
Original Statement
“CCH-aaes−treated women were 5.9 times more likely than placebo-treated women to be ≥2-level composite responders at Day 71 (odds ratio [95% confidence interval], 5.9 [2.2–15.4]; P < 0.001).”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
definitive
Can make definitive causal claims
Assessment Explanation
The study is a pooled analysis of two phase-3 RCTs with randomization, blinding, and placebo control, meeting Level 1a evidence standards. The verb 'causes' is appropriate for establishing causation in this context.
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Systematic Review & Meta-AnalysisLevel 1aIn EvidenceConsistent causal effect of CCH-aaes on cellulite severity across multiple RCTs in diverse populations.
Consistent causal effect of CCH-aaes on cellulite severity across multiple RCTs in diverse populations.
What This Would Prove
Consistent causal effect of CCH-aaes on cellulite severity across multiple RCTs in diverse populations.
Ideal Study Design
A systematic review and meta-analysis of all randomized, double-blind, placebo-controlled trials of CCH-aaes (0.84 mg per session, three sessions over 43 days) in adult women aged 18–75 with moderate-to-severe buttock cellulite (CR-PCSS/PR-PCSS ≥3), measuring ≥2-level composite response at 71 days as the primary endpoint, with sample size ≥1000 total participants.
Limitation: Cannot establish long-term durability or effects in populations not included in original trials (e.g., men, mild cellulite).
Randomized Controlled TrialLevel 1bIn EvidenceCausal effect of CCH-aaes on cellulite severity in a single, well-controlled population.
Causal effect of CCH-aaes on cellulite severity in a single, well-controlled population.
What This Would Prove
Causal effect of CCH-aaes on cellulite severity in a single, well-controlled population.
Ideal Study Design
A double-blind, placebo-controlled RCT of 400 adult women aged 20–70 with moderate-to-severe buttock cellulite (CR-PCSS/PR-PCSS ≥3), randomized to receive three subcutaneous injections of CCH-aaes 0.84 mg or placebo at Days 1, 22, and 43, with primary outcome being ≥2-level composite improvement on CR-PCSS and PR-PCSS at Day 71.
Limitation: Limited to short-term outcomes (≤71 days) and specific demographic group.
Prospective Cohort StudyLevel 2bReal-world effectiveness and durability of CCH-aaes over time in routine clinical practice.
Real-world effectiveness and durability of CCH-aaes over time in routine clinical practice.
What This Would Prove
Real-world effectiveness and durability of CCH-aaes over time in routine clinical practice.
Ideal Study Design
A prospective cohort study following 500 adult women treated with CCH-aaes (0.84 mg ×3) for moderate-to-severe buttock cellulite in dermatology clinics, measuring composite cellulite severity, patient satisfaction, and adverse events at 6, 12, and 24 months post-treatment.
Limitation: Cannot rule out confounding from concurrent treatments or lifestyle changes.
Case-Control StudyLevel 3bAssociation between CCH-aaes treatment and cellulite improvement in a retrospective setting.
Association between CCH-aaes treatment and cellulite improvement in a retrospective setting.
What This Would Prove
Association between CCH-aaes treatment and cellulite improvement in a retrospective setting.
Ideal Study Design
A case-control study comparing 200 women with ≥2-level cellulite improvement after CCH-aaes (cases) to 200 women with no improvement (controls), matched for age, BMI, and baseline severity, to assess predictors of response.
Limitation: Prone to recall and selection bias; cannot establish causation.
Animal Model StudyLevel 5Biological mechanism of collagenase-induced septae lysis and tissue remodeling in cellulite-like structures.
Biological mechanism of collagenase-induced septae lysis and tissue remodeling in cellulite-like structures.
What This Would Prove
Biological mechanism of collagenase-induced septae lysis and tissue remodeling in cellulite-like structures.
Ideal Study Design
A study using porcine or transgenic mouse models with induced subcutaneous fibrotic septae and adipose protrusions, treated with CCH-aaes (0.84 mg equivalent dose), followed by histological analysis of collagen degradation, neocollagenesis, and adipose reorganization at 7, 14, and 28 days.
Limitation: Cannot confirm human efficacy or safety; anatomical differences limit translation.
Evidence from Studies
Supporting (1)
Collagenase Clostridium Histolyticum-aaes for Treatment of Cellulite: A Pooled Analysis of Two Phase-3 Trials
This study gave women a special injection in their buttocks three times over six weeks and found it made cellulite look much better — and it worked nearly six times better than a fake treatment.